[1] Schouten J,Michielsen PP. Treatment of cirrhotic ascites. Acta Gastroenterol Belg,2007,70（2）:217-222.
[2] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis. J Hepatol,2010,53（3）:397-417.
[3] Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012.Hepatology,2013,57（4）:1651-1653.
[4] Okita K,Sakaida I,Okada M,et al. A multicenter,open-label, dose-ranging study to exploratively evaluate the efficacy,safety and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol,2010,45（9） :979-987.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[6] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）. 临床肝胆病杂志,2011,27（11）:1141-1159.
[7] Salerno F,Gerbes A,Gines P,et al.Diagnosis,prevention and treatment of hepetorenal syndrome in cirrhosis. Gut,2007,56（9）:1310-1318.
[8] 赵守松. 肝肾综合征的研究现状. 实用肝脏病杂志,2006,9（1）:58-61.
[9] 乔飞,汪茂荣,何长伦,等. 肝硬化顽固性腹水早期预测及相关因素分析. 实用肝脏病杂志,2008,11（5）:312-314.
[10] 刘红虹,罗生强,福军亮,等 肝硬化顽固性腹水的治疗新进展. 实用肝脏病杂志,2011,14（4）:317-320.
[11] Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure,nephrotic syndrome, cirrhosis,and pregancy. N Engl J Med,1988,319:1127-1134.
[12] Lieberman FL. Overflow theory of ascites formation. Gastroenterology,1989,96:274.
[13] Gattoni A,Marotta F,Vangieri B,et al. Hepatorenal syndrome. Clin Ter,2004,155:375-389.
[14] Levy M,Wexler MJ. Hepatic denervation alters first-phase urinary sodium excretion in dogs with cirrhosis. Am J Physiol,1987,253:F664-F671.
[15] Kostreva DR,Castaner A,Kampine JP. Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol,1980,238:R390-R394.
[16] Bernardi M,Fornalè L,Di Marco C,et al. Hyperdynamic circulation of advanced cirrhosis:a re-appraisal based on posture-induced changes in hemodynamics. J Hepatol,1995,22:309-318.
[17] Schrier RW. Decreased effective blood volume in edematous disorders:what does this mean ?J Am Soc Nephrol,2007,18: 2028-2031.
[18] Leiva JG,Salgado JM,Estradas J,et al. Pathophysiology of ascites and dilutional hyponatremia:contemporary use of aquaretic agents. Ann Hepatol,2007,6:214-221.
[19] Lehrich RW,Greenberg A. Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients. J Intensive Care Med,2012,27（4）:207-218.
[20] Habib S,Boyer TD. Vasopressin V2-receptor antagonists in patients with cirrhosis,ascites and hyponatremia. Therap Adv Gastroenterol,2012,5（3）:189-197.
[21] Yi JH,Shin HJ,Kim HJ. V2 receptor antagonist:tolvaptan. Electrolyte Blood Press,2011,9（2）:50-54.
[22] Schrier RW,Gross P,Gheorghiade M,et al. Tolvaptan,a selective oral vasopressin V2-receptor antagonist,for hyponatremia. N Engl J Med,2006,355（20）:2099-2112.
[23] Cárdenas A,Ginès P,Marotta P,et al. Tolvaptan,an oral vasopressin antagonist,in the treatment of hyponatremia in cirrhosis. J Hepatol,2012,56（3）:571-578.
[24] Dasta JF,Chiong JR,Christian R,et al. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion,based on SALT-1 and SALT-2 trials. Hosp Pract,2012,40（1）:7-14.
[25] Cho C,Logan JL,Lien YH. Massive aquaresis after tolvaptan administration and albumin infusion in a patient with alcoholic cirrhosis. Am J Med,2012,125（1）:e5-6.
[26] Salerno F,Merli M,Riggio O,et al. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology,2004,40:629-635.
[27] Wong F,Watson H,Gerbes A,et al. Satavaptan for the management of ascites in cirrhosis:efficacy and safety across the spectrum of ascites severity. Gut,2012,6（1）:108-116. |
